214 related articles for article (PubMed ID: 24212378)
1. In vitro predictability of drug-drug interaction likelihood of P-glycoprotein-mediated efflux of dabigatran etexilate based on [I]2/IC50 threshold.
Kishimoto W; Ishiguro N; Ludwig-Schwellinger E; Ebner T; Schaefer O
Drug Metab Dispos; 2014 Feb; 42(2):257-63. PubMed ID: 24212378
[TBL] [Abstract][Full Text] [Related]
2. Impact of endogenous esterase activity on in vitro p-glycoprotein profiling of dabigatran etexilate in Caco-2 monolayers.
Ishiguro N; Kishimoto W; Volz A; Ludwig-Schwellinger E; Ebner T; Schaefer O
Drug Metab Dispos; 2014 Feb; 42(2):250-6. PubMed ID: 24212377
[TBL] [Abstract][Full Text] [Related]
3. The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672.
Elsby R; Gillen M; Butters C; Imisson G; Sharma P; Smith V; Surry DD
Drug Metab Dispos; 2011 Feb; 39(2):275-82. PubMed ID: 21075975
[TBL] [Abstract][Full Text] [Related]
4. Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate.
Zhao Y; Hu ZY
Br J Pharmacol; 2014 Feb; 171(4):1043-53. PubMed ID: 24283665
[TBL] [Abstract][Full Text] [Related]
5. Reduced physiologically-based pharmacokinetic model of dabigatran etexilate-dabigatran and its application for prediction of intestinal P-gp-mediated drug-drug interactions.
Lang J; Vincent L; Chenel M; Ogungbenro K; Galetin A
Eur J Pharm Sci; 2021 Oct; 165():105932. PubMed ID: 34260894
[TBL] [Abstract][Full Text] [Related]
6. Quantitative investigation of the impact of P-glycoprotein inhibition on drug transport across blood-brain barrier in rats.
Sugimoto H; Hirabayashi H; Kimura Y; Furuta A; Amano N; Moriwaki T
Drug Metab Dispos; 2011 Jan; 39(1):8-14. PubMed ID: 20962062
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of A Model-Based Approach for Estimating In Vitro P-Glycoprotein Inhibition Potency in a Transcellular Transport Assay.
Kishimoto W; Ishiguro N; Ludwig-Schwellinger E; Ebner T; Maeda K; Sugiyama Y
J Pharm Sci; 2016 Feb; 105(2):891-896. PubMed ID: 26869433
[TBL] [Abstract][Full Text] [Related]
8. In vitro to in vivo evidence of the inhibitor characteristics of Schisandra lignans toward P-glycoprotein.
Liang Y; Zhou Y; Zhang J; Liu Y; Guan T; Wang Y; Xing L; Rao T; Zhou L; Hao K; Xie L; Wang GJ
Phytomedicine; 2013 Aug; 20(11):1030-8. PubMed ID: 23731657
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?
Hellwig T; Gulseth M
Ann Pharmacother; 2013 Nov; 47(11):1478-87. PubMed ID: 24259602
[TBL] [Abstract][Full Text] [Related]
10. P-glycoprotein mediated efflux in Caco-2 cell monolayers: the influence of herbals on digoxin transport.
Oga EF; Sekine S; Shitara Y; Horie T
J Ethnopharmacol; 2012 Dec; 144(3):612-7. PubMed ID: 23064285
[TBL] [Abstract][Full Text] [Related]
11. Dosing of dabigatran etexilate in relation to renal function and drug interactions at a tertiary hospital.
Chin PK; Vella-Brincat JW; Walker SL; Barclay ML; Begg EJ
Intern Med J; 2013 Jul; 43(7):778-83. PubMed ID: 23611064
[TBL] [Abstract][Full Text] [Related]
12. ITC commentary on the prediction of digoxin clinical drug-drug interactions from in vitro transporter assays.
Lee CA; Kalvass JC; Galetin A; Zamek-Gliszczynski MJ
Clin Pharmacol Ther; 2014 Sep; 96(3):298-301. PubMed ID: 25141954
[TBL] [Abstract][Full Text] [Related]
13. Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein.
Keogh JP; Kunta JR
Eur J Pharm Sci; 2006 Apr; 27(5):543-54. PubMed ID: 16406207
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin.
Stangier J; Stähle H; Rathgen K; Roth W; Reseski K; Körnicke T
J Clin Pharmacol; 2012 Feb; 52(2):243-50. PubMed ID: 21868715
[TBL] [Abstract][Full Text] [Related]
15. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity.
Taub ME; Podila L; Ely D; Almeida I
Drug Metab Dispos; 2005 Nov; 33(11):1679-87. PubMed ID: 16093365
[TBL] [Abstract][Full Text] [Related]
16. Enhancement effect of P-gp inhibitors on the intestinal absorption and antiproliferative activity of bestatin.
Huo X; Liu Q; Wang C; Meng Q; Sun H; Peng J; Ma X; Liu K
Eur J Pharm Sci; 2013 Nov; 50(3-4):420-8. PubMed ID: 23981338
[TBL] [Abstract][Full Text] [Related]
17. Calibration of in vitro multidrug resistance protein 1 substrate and inhibition assays as a basis to support the prediction of clinically relevant interactions in vivo.
Poirier A; Cascais AC; Bader U; Portmann R; Brun ME; Walter I; Hillebrecht A; Ullah M; Funk C
Drug Metab Dispos; 2014 Sep; 42(9):1411-22. PubMed ID: 24939652
[TBL] [Abstract][Full Text] [Related]
18. Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro.
Wandel C; Kim RB; Guengerich FP; Wood AJ
Drug Metab Dispos; 2000 Aug; 28(8):895-8. PubMed ID: 10901697
[TBL] [Abstract][Full Text] [Related]
19. P-glycoprotein is responsible for the poor intestinal absorption and low toxicity of oral aconitine: in vitro, in situ, in vivo and in silico studies.
Yang C; Zhang T; Li Z; Xu L; Liu F; Ruan J; Liu K; Zhang Z
Toxicol Appl Pharmacol; 2013 Dec; 273(3):561-8. PubMed ID: 24120885
[TBL] [Abstract][Full Text] [Related]
20. Interaction of angiotensin II type 1 receptor blockers with P-gp substrates in Caco-2 cells and hMDR1-expressing membranes.
Kamiyama E; Nakai D; Mikkaichi T; Okudaira N; Okazaki O
Life Sci; 2010 Jan; 86(1-2):52-8. PubMed ID: 19914261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
